DPX-0907

Known as: Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907 
A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with immunopotentiating activity. Therapeutic breast/ovarian/prostate… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2014
01220102014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
This review discusses peptide-based vaccines in breast cancer, immune responses and clinical outcomes, which include studies on… (More)
Is this relevant?
Review
2014
Review
2014
In an attempt to significantly enhance immunogenicity of peptide cancer vaccines, we developed a novel non-emulsion depot-forming… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2013
2013
A successful cancer vaccine needs to overcome the effects of immune-suppressor cells such as Treg lymphocytes, suppressive… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
DepoVaxTM is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly enhance the immunogenicity of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2012
2012
The development and validation of an HPLC method for the quantification of eight peptide antigens from the therapeutic cancer… (More)
Is this relevant?
2011
2011
e13050 Background: Immunovaccine Inc. (IMV) has developed a novel liposome-in-oil depot vaccine platform called DepoVax (DPX… (More)
Is this relevant?
2010
2010
In light of lack of efficacy associated with current cancer vaccines, we aimed to develop a novel vaccine platform called DepoVax… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?